


RESEARCH ARTICLE

Open Access



Gestational diabetes mellitus, prenatal maternal depression, and risk for postpartum depression: an Environmental influences on Child Health Outcomes (ECHO) Study

Lauren C. Shuffrey^{1*} , Maristella Lucchini¹, Santiago Morales², Ayesha Sania¹, Christine Hockett³, Emily Barrett⁴, Kecia N. Carroll⁵, Camille C. Cioffi⁶, Dana Dabelea⁷, Sean Deoni⁸, Anne L. Dunlop⁹, Arielle Deutsch³, William P. Fifer¹, Morgan R. Firestein¹, Monique M. Hedderson¹⁰, Melanie Jacobson¹¹, Rachel S. Kelly¹², Jean M. Kerver¹³, W. Alex Mason¹⁴, Hooman Mirzakhani¹⁵, Thomas G. O'Connor¹⁶, Leonardo Trasande¹⁷, Scott Weiss¹⁸, Rosalind Wright⁵, Yeyi Zhu¹⁹, Rosa M. Crum²⁰, Seonjoo Lee²¹, Amy J. Elliott³ and Catherine Monk^{22,23} on behalf of program collaborators for Environmental influences on Child Health Outcomes

Abstract

Background: Prior research has demonstrated bidirectional associations between gestational diabetes mellitus (GDM) and perinatal maternal depression. However, the association between GDM, prenatal depression, and postpartum depression (PPD) has not been examined in a prospective cohort longitudinally.

Methods: Participants in the current analysis included 5,822 women from the National Institutes of Health's Environmental influences on Child Health Outcomes (ECHO) Research Program: $N = 4,606$ with *Neither GDM nor Prenatal Maternal Depression* (Reference Category); $N = 416$ with *GDM only*; $N = 689$ with *Prenatal Maternal Depression only*; and $N = 111$ with *Comorbid GDM and Prenatal Maternal Depression*. The PROMIS-D scale was used to measure prenatal and postnatal maternal depressive symptoms. Primary analyses consisted of linear regression models to estimate the independent and joint effects of GDM and prenatal maternal depression on maternal postpartum depressive symptoms.

Results: A higher proportion of women with GDM were classified as having prenatal depression ($N = 111$; 21%) compared to the proportion of women without GDM who were classified as having prenatal depression ($N = 689$; 13%), however this finding was not significant after adjustment for covariates. Women with *Comorbid GDM and Prenatal Maternal Depression* had significantly increased postpartum depressive symptoms measured by PROMIS-D T-scores compared to women with *Neither GDM nor Prenatal Maternal Depression* (mean difference 7.02, 95% CI 5.00, 9.05). *Comorbid GDM and Prenatal Maternal Depression* was associated with an increased likelihood of PPD (OR 7.38, 95%

*Correspondence: lcg2129@cumc.columbia.edu

¹ Department of Psychiatry, Division of Developmental Neuroscience, Columbia University Irving Medical Center, NYSPI, Pades Rm 4932, 1051 Riverside Drive, New York, NY 10032, USA

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

CI 4.05, 12.94). However, women with *GDM only* did not have increased postpartum PROMIS-D T-scores or increased rates of PPD.

Conclusions: Our findings underscore the importance of universal depression screening during pregnancy and in the first postpartum year. Due to the joint association of GDM and prenatal maternal depression on risk of PPD, future studies should examine potential mechanisms underlying this relation.

Keywords: Gestational diabetes mellitus (GDM), Perinatal depression, Maternal mood disorders, Maternal metabolic disorders

Background

Gestational diabetes mellitus (GDM) is defined as diabetes diagnosed in the second or third trimester of pregnancy that was not clearly present prior to gestation [1]. GDM affects approximately 8.2% of pregnancies in the United States (US) [2] and approximately 14% of pregnancies globally with significant variability in prevalence based on diagnostic criteria, sociodemographic characteristics, and geographic region [3, 4]. GDM is associated with increased risk of birth complications and adverse long-term health outcomes for mothers including cardiometabolic conditions [5]. A growing body of research in pregnant and non-pregnant populations suggests a bidirectional association between diabetes and depression [6–10]. Prior studies have demonstrated women with depression prior to pregnancy are more likely to be diagnosed with GDM and women with GDM are 1.5 times more likely to be diagnosed with postpartum depression (PPD) [11–18]. PPD is among the most common perinatal morbidities affecting approximately 17% of women globally with adverse consequences for maternal health, well-being, and self-care [19, 20].

A recent meta-analysis (2020) examined the association between GDM and depressive symptoms around the time of GDM diagnosis, subsequent to GDM diagnosis, and in the postpartum period [21]. Despite significant heterogeneity in participant sociodemographic characteristics across included studies, GDM was associated with increased prenatal depressive symptoms around the time of GDM diagnosis with a pooled odds ratio (OR) of 2.08 (95% CI 1.42, 3.05) and increased prenatal depressive symptoms following GDM diagnosis with a pooled OR of 1.41 (95% CI 0.88, 2.25) [21]. GDM status also was associated with PPD with a pooled OR of 1.59 (95% CI 1.26, 2.00) [21]. Prior research from US based samples also indicates GDM and perinatal depression may both disproportionately affect women who self-identify as non-White or Hispanic [22–26], likely due to health determinants such as poverty, systemic racism, history of trauma, and limited access to health and mental health care resources [27, 28]. Specifically, studies examining racial or ethnic disparities in pregnancy conditions have reported women who identify as Hispanic or Latina and/


or Asian have an increased incidence of GDM compared to non-Hispanic White women [23]. For example, approximately 15% of women who self-identify as South-east Asian develop GDM during pregnancy compared to approximately 4% of non-Hispanic White women [22]. Studies examining the incidence of perinatal mood disorders have reported Black or African American and American Indian/Alaskan Native women have increased incidence of perinatal depression compared to non-Hispanic White women [24].

Despite increased risk of adverse long-term outcomes for both mothers and their children, the association between comorbid GDM and prenatal depression in relation to PPD risk has not been examined in a single longitudinal analysis using a prospective cohort design. Studies to date have assessed associations between GDM and prenatal or postnatal depression rather than examining their comorbidity in predicting PPD or postpartum symptoms. Thus, our objective was to determine the joint and independent associations of GDM and prenatal maternal depression on PPD. Given the high co-occurrence of these disorders, particularly in diverse populations, there is important public health and clinical value to understanding their impact on PPD with implications for both maternal and child well-being.

Methods

Study design and participants

Data for this analysis were collected through the National Institutes of Health's (NIH) Environmental influences on Child Health outcomes (ECHO) Research Program. Participants in the current analysis included pregnant individuals with complete information regarding GDM status (GDM during pregnancy vs. no GDM during pregnancy), at least one prenatal self-reported depression assessment, and a minimum of one self-reported postnatal depression assessment collected during the first postpartum year ($N=5866$). Exclusion criteria consisted of Type 1 or Type 2 diabetes. After exclusions a total of 5,822 maternal participants across 16 cohorts, enrolled from thirteen US states and Puerto Rico, met criteria and were included in the current analysis (Fig. 1). The study protocol was approved by the local or single ECHO institutional



review board. Written informed consent was obtained from all participants for ECHO-wide Cohort Data Collection Protocol participation and for participation in specific cohorts. Both a central and cohort-specific institutional review board monitored human subject activities at each cohort site and the centralized ECHO Data Analysis Center. The ECHO-wide protocol is approved under a single IRB, which is of Western Institutional Review Board (WIRB) Copernicus Group IRB. CG IRB is registered with the Office for Human Research Protections (OHRP and FDA) as IRB00000533.

Gestational diabetes mellitus

Information regarding GDM during pregnancy was harmonized across ECHO cohorts (Supplement). All participants had complete information regarding GDM status during pregnancy.

NIH Patient-Reported Outcomes Measurement Information System Depression Scale (PROMIS[®]-D)

The PROMIS-D scale [32] was utilized by the NIH's ECHO Research Program to harmonize various different self-report depression instruments used by individual cohorts to one common scale (Supplement). PROMIS-D T-scores are referenced to a mean of 50 and standard deviation of 10 with respect to the general adult US population, such that individuals with T-scores of 50 have

depressive symptom severity equal to the mean in the general adult US population. PROMIS-D cutoff scores were derived from item response theory (IRT)-based differential item function (DIF) analyses suggesting specific cutoffs based on the original assessment scale harmonized to PROMIS-D T-scores (see Supplement). In the absence of IRT based cutoff scores, a PROMIS-D T-score cutoff of 60 or higher was utilized to indicate clinical levels of depression based on existing literature [33–35].

Sociodemographic and medical history

Covariates described below were harmonized across ECHO cohorts based on either maternal self-report using ECHO case report forms or through maternal-infant medical record abstraction.

Statistical analyses

All statistical analyses were conducted in R version 4.1.0 in a secure virtual private network platform hosted by the Research Triangle Institute (RTI) using de-identified data. Demographic differences between the GDM and non-GDM groups were examined using Chi Square or Fisher's Exact Test. We examined if women with GDM had increased prenatal depressive symptoms using linear regression models in unadjusted, partially adjusted, and fully adjusted models (described below). We additionally examined if women with GDM were more likely to

be classified as having clinical levels of prenatal maternal depression based on PROMIS-D cutoff scores using Chi Square analysis. *Post-hoc* analyses analysis consisted of logistic regression to examine the likelihood of prenatal maternal depression based on PROMIS-D cutoff scores by GDM status in unadjusted, partially adjusted, and fully adjusted models (described below). Primary analyses consisted of linear regression models to estimate the independent and joint effects of GDM and prenatal maternal depression on maternal postpartum depressive symptoms operationalized by continuous PROMIS-D T-scores during the first postpartum year. We created a GDM-depression variable with four categories:

- (1) Neither GDM nor Prenatal Maternal Depression ($N=4,606$, Reference Category);
- (2) GDM only ($N=416$);
- (3) Prenatal Maternal Depression Only ($N=689$).
- (4) Comorbid GDM and Prenatal Maternal Depression ($N=111$).

GDM-depression groups were created on the basis of maternal GDM status (yes or no) and based on PROMIS-D cutoff scores to indicate clinical levels of depression (prenatal maternal depression yes or no). We implemented unadjusted, partially adjusted, and fully adjusted models. Unadjusted models included only the original depression instrument as a covariate. Partially adjusted models additionally adjusted for maternal race, ethnicity, age at delivery in years, highest educational attainment, gestational hypertension, and pre-pregnancy body mass index (BMI) categorized as either underweight/normal-weight or overweight/obese. Fully adjusted models additionally adjusted for delivery mode (vaginal vs. cesarean) and preterm delivery (less than 37 weeks' gestation). Covariates included in partially and fully adjusted models were chosen a priori based on prior research in this domain. Missing data for covariates in the partially and fully adjusted models were handled using the missing-indicator method (Tables 1 and 2). We report standardized mean differences with confidence intervals (95% CI) and estimated marginal means for the fully adjusted models as our primary analysis. Secondary analyses consisted of logistic regression to examine the likelihood of maternal PPD based on PROMIS-D cutoff scores by GDM-depression category. *Post-hoc* analyses consisted of refitting primary fully adjusted models to estimate the independent and joint effects of GDM and prenatal maternal depression on maternal postpartum depressive symptoms stratified separately by Hispanic ethnicity and pre-pregnancy BMI categorized as overweight or obese (Supplement). In a sensitivity analysis, we refit a fully adjusted model including a cohort that contributed $\geq 20\%$

of overall data (Supplement). The significance threshold for all analyses was set at $p < 0.05$.

Results

Study population

The final sample consists of 5,822 participants; $N=527$ diagnosed with GDM and $N=5,295$ without GDM (Table 1). The prevalence of GDM in our analysis was 9.95%. Compared to the non-GDM group, a greater proportion of women with GDM self-identified as Asian ($X^2=26.73$, $p < 0.0001$), mixed race ($X^2=46.50$, $p < 0.0001$) or Hispanic ($X^2=122.13$, $p < 0.0005$) and a lower proportion identified as Black ($X^2=34.74$, $p < 0.0001$) or White ($X^2=10.28$, $p < 0.0005$). The prevalence of GDM was 18.59% among women who self-identified as Asian, 17.14% among women who self-identified as Hispanic, and 15.76% among women who self-identified as mixed race. Women with GDM were more likely to report lower levels of educational attainment ($X^2=27.70$, $p < 0.0001$) and were more likely to be overweight or obese prior to pregnancy compared to women without GDM ($X^2=79.34$, $p < 0.0001$). Women with GDM were also more likely to deliver via cesarean ($X^2=24.78$, $p < 0.0001$) or preterm ($X^2=4.28$, $p < 0.05$). When dichotomized into non-clinical versus clinically elevated symptoms based on PROMIS-D cutoff scores, the prevalence of prenatal maternal depression in our analysis was 13.74%. When further grouping by *No GDM or Prenatal Maternal Depression* ($N=4,606$), *GDM only* ($N=416$), *Prenatal Maternal Depression Only* ($N=689$), and *GDM and Prenatal Maternal Depression* ($N=111$), sociodemographic differences persisted in race, ethnicity, educational attainment, pre-pregnancy weight, delivery mode, and in preterm delivery rates (Table 2).

Association between GDM and prenatal maternal depression

Linear regression models showed that compared to women without GDM, women with GDM did not have significantly increased prenatal maternal PROMIS-D T-scores in unadjusted, partially adjusted, or fully adjusted models (p -values > 0.05). Based on dichotomized non-clinical (no prenatal depression) versus clinically elevated symptoms (prenatal depression) using PROMIS-D cutoff scores, a higher proportion of women with GDM ($N=527$) were classified as having prenatal depression ($N=111$; 21%) compared to the proportion of women without GDM who were classified as having prenatal depression ($N=689$; 13%). However, logistic regression analyses to examine the likelihood of prenatal maternal depression among women with and without GDM were not significant ($p > 0.05$).

Table 1 Maternal demographic information by GDM Status in ECHO participants

	GDM (N = 527)	Non-GDM (N = 5295)	Overall (N = 5822)
Race			
American Indian or Alaskan Native	< 5 (< 1%)	< 45 (< 1%)	< 50 (< 1%)
Asian	45 (8.5%)	197 (3.7%)	242 (4.2%)
Black	71 (13.5%)	1328 (25.1%)	1399 (24.0%)
Mixed Race	119 (22.6%)	636 (12.0%)	755 (13.0%)
Native Hawaiian or Other Pacific Islander	< 35 (< 5%)	< 35 (< 1%)	< 55 (< 1%)
White	259 (49.1%)	2993 (56.5%)	3252 (55.9%)
Missing	< 10 (< 2%)	< 70 (< 2%)	< 80 (< 2%)
Ethnicity			
Hispanic or Latino	210 (39.8%)	1015 (19.2%)	1225 (21.0%)
Non-Hispanic or Latino	315 (59.8%)	4273 (80.7%)	4588 (78.8%)
Missing	< 5 (< 1%)	< 10 (< 1%)	< 10 (< 1%)
Highest Educational Attainment			
Less than high school	63 (12.0%)	328 (6.2%)	391 (6.7%)
High School degree, GED, or equivalent	89 (16.9%)	565 (10.7%)	654 (11.2%)
Associates degree or trade school	95 (18.0%)	802 (15.1%)	897 (15.4%)
Bachelor's degree	83 (15.7%)	1070 (20.2%)	1153 (19.8%)
Master's degree or higher	111 (21.1%)	1146 (21.6%)	1257 (21.6%)
Missing	86 (16.3%)	1384 (26.1%)	1470 (25.2%)
Age at Delivery (years)			
Mean (SD)	32.5 (6.21)	30.0 (5.94)	30.2 (6.00)
Missing	< 5 (< 1%)	< 5 (< 1%)	< 10 (< 1%)
Pre-pregnancy BMI Category			
Underweight or normal weight	152 (28.8%)	2563 (48.4%)	2715 (46.6%)
Overweight or obese	318 (60.3%)	2419 (45.7%)	2737 (47.0%)
Missing	57 (10.8%)	313 (5.9%)	370 (6.4%)
Delivery Mode			
Vaginal	320 (60.7%)	3703 (69.9%)	4023 (69.1%)
Cesarean	194 (36.8%)	1414 (26.7%)	1608 (27.6%)
Missing	13 (2.5%)	178 (3.4%)	191 (3.3%)
Preterm Birth (< 37 weeks' gestation)			
Term	478 (90.7%)	4936 (93.2%)	5414 (93.0%)
Preterm	49 (9.3%)	359 (6.8%)	408 (7.0%)

Association between GDM, prenatal maternal depression, and postpartum depression

Linear regression models showed that women with *Prenatal Maternal Depression Only* and women with *Comorbid GDM and Prenatal Maternal Depression* had increased postpartum PROMIS-D T-scores in unadjusted ($F(6, 5815) = 59.9, p < 0.0001, \text{adj. } R^2 = 0.06$), partially adjusted ($F(23, 5798) = 19.28, p < 0.0001, \text{adj. } R^2 = 0.07$), and fully adjusted models ($F(26, 5795) = 18.25, p < 0.0001, \text{adj. } R^2 = 0.07$) (Table 3). In the fully adjusted model, general linear hypothesis testing using Tukey pairwise contrasts showed women with *Prenatal Maternal Depression Only* (adjusted marginal mean 49.8, 95% CI 45.4, 54.2)

had significantly increased postpartum PROMIS-D T-scores compared to women with *Neither GDM nor Prenatal Maternal Depression* (adjusted marginal mean 42.8, 95% CI 39.4, 48.1; mean difference 6.06, 95% CI 5.17, 6.94) (Table 3). Women with *Comorbid GDM and Prenatal Maternal Depression* (adjusted marginal mean 50.8, 95% CI 46.2, 55.4) also had significantly increased postpartum PROMIS-D T-scores compared to women with *Neither GDM nor Prenatal Maternal Depression* (mean difference 7.02, 95% CI 5.00, 9.05) (Table 3). However, there was no significant pairwise difference in postpartum PROMIS-D T-scores between women with *GDM only* as compared to *Neither GDM nor Prenatal Maternal*

Table 2 Maternal demographic information by GDM-Prenatal Depression Group

	No GDM or Prenatal Maternal Depression (N = 4606)	GDM Only (N = 416)	Prenatal Maternal Depression Only (N = 689)	GDM and Prenatal Maternal Depression (N = 111)	Overall Sample (N = 5822)
Race					
American Indian or Alaskan Native	40 (0.9%)	< 5 (< 1%)	< 5 (< 1%)	< 5 (< 1%)	< 50 (< 1%)
Asian	152 (3.3%)	34 (8.2%)	45 (6.5%)	11 (9.9%)	242 (4.2%)
Black	1187 (25.8%)	59 (14.2%)	141 (20.5%)	12 (10.8%)	1399 (24.0%)
Mixed Race	470 (10.2%)	88 (21.2%)	166 (24.1%)	31 (27.9%)	755 (13.0%)
Native Hawaiian or Other Pacific Islander	< 35 (1%)	< 15 (< 4%)	< 10 (2%)	< 10 (6%)	< 55 (1%)
White	2680 (58.2%)	213 (51.2%)	313 (45.4%)	46 (41.4%)	3252 (55.9%)
Missing	< 55 (< 2%)	< 10 (< 2%)	< 14 (< 3%)	< 5 (4%)	< 80 (< 2%)
Ethnicity					
Hispanic or Latino	768 (16.7%)	152 (36.5%)	247 (35.8%)	58 (52.3%)	1225 (21.0%)
Non-Hispanic or Latino	3832 (83.2%)	264 (63.5%)	441 (64.0%)	51 (45.9%)	4588 (78.8%)
Missing	< 5 (< 1%)	< 5 (< 1%)	< 5 (< 1%)	< 5 (< 1%)	< 10 (< 1%)
Highest Educational Attainment					
Associates degree or trade school	673 (14.6%)	72 (17.3%)	129 (18.7%)	23 (20.7%)	897 (15.4%)
Bachelor's degree	933 (20.3%)	65 (15.6%)	137 (19.9%)	18 (16.2%)	1153 (19.8%)
High School degree, GED, or equivalent	452 (9.8%)	64 (15.4%)	113 (16.4%)	25 (22.5%)	654 (11.2%)
Less than high school	243 (5.3%)	48 (11.5%)	85 (12.3%)	15 (13.5%)	391 (6.7%)
Master's degree or higher	978 (21.2%)	88 (21.2%)	168 (24.4%)	23 (20.7%)	1257 (21.6%)
Missing	1327 (28.8%)	79 (19.0%)	57 (8.3%)	7 (6.3%)	1470 (25.2%)
Age at Delivery (years)					
Mean (SD)	29.9 (5.91)	32.4 (6.06)	30.7 (6.07)	32.7 (6.78)	30.2 (6.00)
Missing	< 5 (< 1%)	< 5 (< 1%)	< 5 (< 1%)	< 5 (< 1%)	< 10 (< 1%)
Pre-pregnancy BMI Category					
Overweight or obese	2135 (46.4%)	255 (61.3%)	284 (41.2%)	63 (56.8%)	2737 (47.0%)
Underweight or normal weight	2236 (48.5%)	120 (28.8%)	327 (47.5%)	32 (28.8%)	2715 (46.6%)
Missing	235 (5.1%)	41 (9.9%)	78 (11.3%)	16 (14.4%)	370 (6.4%)
Delivery Mode					
Cesarean	1230 (26.7%)	155 (37.3%)	184 (26.7%)	39 (35.1%)	1608 (27.6%)
Vaginal	3216 (69.8%)	249 (59.9%)	487 (70.7%)	71 (64.0%)	4023 (69.1%)
Missing	160 (3.5%)	12 (2.9%)	18 (2.6%)	1 (0.9%)	191 (3.3%)
Preterm Birth (< 37 weeks' gestation)					
Preterm	295 (6.4%)	34 (8.2%)	64 (9.3%)	15 (13.5%)	408 (7.0%)
Term	4311 (93.6%)	382 (91.8%)	625 (90.7%)	96 (86.5%)	5414 (93.0%)

Depression (Table 3). Women with *Comorbid GDM and Prenatal Maternal Depression* also had significantly increased postpartum PROMIS-D T-scores compared to women with *GDM Only* (mean difference 6.71, 95% CI 4.51, 8.92), but not compared to *Prenatal Maternal Depression Only*.

GDM, Prenatal maternal depression, and odds of postpartum depression

Logistic regression was performed to ascertain the effects of GDM and prenatal maternal depression on postnatal

maternal depressive symptoms when dichotomized into non-clinical (no PPD) versus clinically elevated symptoms (PPD) using PROMIS-D cutoff scores. Based on this categorization, the prevalence of PPD in our analysis was 5.55%. *Prenatal Maternal Depression Only* was associated with PPD in unadjusted ($X^2 = 119.6, p < 0.0001$), partially adjusted ($X^2 = 102.9, p < 0.0001$), and fully adjusted models ($X^2 = 101.2, p < 0.0001$) (Table 4). *Comorbid GDM and Prenatal Maternal Depression* also was associated with PPD in unadjusted ($X^2 = 59.1, p < 0.0001$), partially adjusted ($X^2 = 48.2, p < 0.0001$), and fully adjusted models

($X^2 = 46.1, p < 0.0001$) (Table 4). *GDM Only* was not associated with PPD in unadjusted, partially adjusted, or fully adjusted models (p -values > 0.05) (Table 4). In the fully

adjusted model, *Comorbid GDM and Prenatal Maternal Depression* (OR 7.38, 95% CI 4.05, 12.94) was associated with an increased likelihood of PPD (Fig. 2). *Prenatal*

Table 3 Association between GDM, prenatal maternal depression, and postpartum depression: pairwise contrasts

Pairwise Comparisons	Mean Difference in Postpartum PROMIS T Scores \pm Standard Error of Difference	Fully Adjusted ^a		
		Mean Difference (95% CI)	t-statistic	p-value
<i>GDM Only – Neither GDM nor Prenatal Maternal Depression</i>	0.31 \pm 0.42	-0.77, 1.40	0.73	0.47
<i>Prenatal Maternal Depression Only – Neither GDM nor Prenatal Maternal Depression</i>	6.06 \pm 0.35	5.17, 6.94	17.29	< 0.0001
<i>GDM and Prenatal Maternal Depression – Neither GDM nor Prenatal Maternal Depression</i>	7.03 \pm 0.80	5.00, 9.05	8.76	< 0.0001
<i>Prenatal Maternal Depression Only – GDM only</i>	5.74 \pm 0.51	4.45, 7.04	11.23	< 0.0001
<i>GDM and Prenatal Maternal Depression – GDM Only</i>	6.71 \pm 0.87	4.51, 8.92	7.70	< 0.0001
<i>GDM and Prenatal Maternal Depression – Prenatal Maternal Depression Only</i>	0.97 \pm 0.84	-1.14, 3.08	1.16	0.25

^a Fully adjusted models include the original depression instrument, maternal race, ethnicity, age at delivery, educational attainment, gestational hypertension, pre-pregnancy body mass index, delivery mode, and preterm birth status

Table 4 Association between GDM, prenatal maternal depression, and likelihood of postpartum depression

Groups	No PPD	PPD	Fully Adjusted ^a				
			z-statistic	X ² Value	p-value	Odds Ratio	95% CI of Odds Ratio
<i>Neither GDM nor Prenatal Maternal Depression</i>	4428	178	Reference	Reference	Reference	Reference	Reference
<i>GDM only</i>	398	18	0.98	0.96	0.32	1.28	0.75, 2.09
<i>Prenatal Maternal Depression Only</i>	598	91	10.06	101.2	< 0.0001	4.60	3.41, 6.18
<i>GDM and Prenatal Maternal Depression</i>	92	19	6.77	46.1	< 0.0001	7.38	4.05, 12.94
Overall	5516	306					

^a Fully adjusted models include the original depression instrument, maternal race, ethnicity, age at delivery, educational attainment, gestational hypertension, pre-pregnancy body mass index, delivery mode, and preterm birth status




Fig. 2 GDM, Prenatal Depression, and Likelihood of Postpartum Depression. The x-axis displays odds ratios (ORs) from fully adjusted models (controlling for the original depression instrument, maternal race, ethnicity, age at delivery, educational attainment, gestational hypertension, pre-pregnancy body mass index, delivery mode, and preterm birth status) and the 95% CI of the ORs for each GDM-depression category (y-axis). *** denotes significance at the 0.0001 level

Maternal Depression Only was also associated with an increased likelihood of PPD (OR 4.60, 95% CI 3.41, 6.18) (Fig. 2). However, *GDM Only* was not associated with an increased likelihood of PPD (OR 1.28, 95% CI 0.75, 2.09) (Fig. 2).

Discussion

To our knowledge the present analysis is the largest to date to examine associations among GDM and depression. It is also the first longitudinal analysis to examine the association between GDM and postpartum depression in the absence of prenatal maternal depression and, separately, comorbid GDM and prenatal maternal depression, with postpartum depression. In the present analysis, the prevalence of GDM and prenatal maternal depression were 9.95% and 13.74% respectively, which are comparable to the estimated GDM and prenatal maternal depression prevalence in the US [36, 37]. Similar to prior work [23], we observed participants with GDM were more likely to self-identify as Asian, mixed race, or Hispanic and were less likely to self-identify as White. In our analysis, the prevalence of GDM was 18.59% among women who self-identified as Asian, 17.14% among women who self-identified as Hispanic, and 15.76% among women who self-identified as mixed race, which reflect sociodemographic and geographic differences in the prevalence of GDM reported in the US [2] and globally [3]. However, the prevalence of PPD in our analysis was 5.55% which is lower than the estimated prevalence of PPD in the US [20]. This may be reflective of the EPDS to PROMIS-D harmonization underestimating depression or due to research referrals for perinatal depression treatment during the study resulting in a lower prevalence.

To summarize our findings examining the association between GDM and prenatal maternal depressive symptoms, in this analysis we did not find increased levels of prenatal maternal depressive symptoms in women with GDM compared to women without GDM. Based on dichotomized non-clinically relevant versus clinically relevant prenatal PROMIS-D T-scores, women with GDM had an increased prevalence of prenatal maternal depression using Chi Square analysis. However, in contrast to most prior analyses [21] our logistic regression analyses examining the likelihood of prenatal maternal depression among women with GDM was not significant after adjusting for covariates. There are several differences between our analysis and prior research to date that may account for the divergent findings. Some possible explanations include differences in prenatal maternal depression scores, differences in the timing of prenatal maternal depression measurement, and/or geographic or sociodemographic differences between cohorts.

In summary of our findings examining the joint and independent associations between GDM and prenatal maternal depression on postpartum maternal depressive symptoms and likelihood of PPD, as expected based on prior research, prenatal maternal depression was associated with increased postpartum depressive symptoms and an increased likelihood of PPD. As hypothesized, comorbid GDM and prenatal maternal depression was associated with increased postpartum maternal depressive symptoms compared to neither GDM nor prenatal maternal depression. However, in the absence of prenatal maternal depression, GDM was not associated with increased postpartum maternal depressive symptoms compared to neither GDM nor prenatal maternal depression. Finally, as hypothesized, we found that comorbid GDM and prenatal maternal depression was associated with a greater likelihood of PPD (OR 7.38, 95% CI 4.05, 12.94) compared to neither GDM nor prenatal maternal depression and the highest OR. However, GDM in the absence of prenatal maternal depression was not associated with an increased likelihood of PPD (OR 1.28, 95% CI 0.75, 2.09). The lack of association between GDM in the absence of prenatal maternal depression with postpartum maternal depressive symptoms and PPD suggests unmeasured prenatal maternal depression may have been a potential confound in prior analyses. Therefore, all three variables should be considered in subsequent analyses attempting to dissect these associations.

Significant strengths of our analysis include our large sample size leveraging the ECHO study that includes participant representation from thirteen US States and Puerto Rico, the diversity of our participant population with 43% of participants self-identifying as non-White and/or Hispanic, and having both a prenatal and postpartum assessment of maternal depressive symptoms. However, several limitations must be taken into consideration when interpreting our findings. There are several factors that should be explored in future analyses that we were unable to consider due to constraints in harmonization across ECHO cohorts or the percentage of missing data. For example, we did not have information on the gestational week of GDM diagnosis, GDM treatment, the presence of GDM in a prior pregnancy, prior pregnancy losses, perinatal depression treatment such as therapies or pharmaceutical interventions, food insecurity, or social support during the perinatal period, which are all potential unobserved confounders. Data regarding parity, prenatal or postnatal mental health diagnoses, employment status, household income, and infant NICU status were missing for greater than 50% of participants. Additionally, there is some evidence of increased postpartum anxiety in women with GDM [38, 39], however

harmonized anxiety measures were not available for participants included in the present analysis.

Conclusions

Despite these limitations, our findings have important clinical and research implications: They underscore the importance of universal depression screening during pregnancy and through the first year postpartum [40]; identification of the interactions of different biological mechanisms underlying GDM, prenatal depression, and risk of PPD is needed to mitigate adverse maternal mental health outcomes. These findings suggest women with GDM and prenatal maternal depression should receive additional monitoring for postpartum mood disorders. Additionally, due to the joint association of GDM and prenatal maternal depression on risk of PPD, two conditions associated with increased subclinical levels of inflammation [6–10, 41, 42], future studies should examine potential mechanisms underlying this relation. Further understanding of mechanisms may inform prophylactic programs during pregnancy to prevent or treat postpartum mood disorders with the potential to improve long-term dyadic outcomes for mothers and their children.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12884-022-05049-4>.

Additional file 1.

Acknowledgements

We would like to thank the Environmental influences on Child Health Outcomes program collaborators and participants.

Authors' contributions

LCS and CM contributed to the conception and design of the work; CH, EB, KNC, CCC, DB, SD, ALD, AD, MJ, RSK, JMK, WAM, HM, TGO, LT, SW, RW, & AJE contributed to data acquisition. LCS, ML, SM, AS, DD, MJ, SL, and CM contributed to data analysis and interpretation. All authors (LCS, ML, SM, AS, CH, EB, KNC, CCC, DB, SD, ALD, AD, WPF, MRF, MMH, MJ, RSK, JMK, WAM, HM, TGO, LT, SW, RW, YZ, RMC, SL, AJE, and CM) contributed to drafting the work and substantively revising it. All authors contributed to critical review and revision of the manuscript. All authors read and approved the final manuscript and agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Funding

Research reported in this publication was supported by the Environmental influences on Child Health Outcomes (ECHO) program, Office of the Director, National Institutes of Health, under Award Numbers U2COD023375 (Coordinating Center), U24OD023382 (Data Analysis Center), U24OD023319 (PRO Core). The following grants supported data collection: UH3 OD023248 (DABELEA), UH3 OD023313 (DEONI), UH3 OD023328 (MONK), UH3 OD023318 (DUNLOP), UH3 OD023279 (ELLIOTT), UH3 OD023349 (O'CONNOR), UH3 OD023285 (KERVER), UH3 OD023271 (BARRETT), UH3 OD023305 (TRASANDE), UH3 OD023337 (WRIGHT), UH3 OD023389 (LEVE), and UH3 OD023289 (ZHU).

Dr. Lauren Shuffrey is supported by K99HD103910 issued by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development. Dr. Ayesha Sania is supported by UH3OD023279-05S1, re-entry supplement from Office of the Director, NIH, and Office of Research on Women Health (ORWH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Availability of data and materials

The datasets for this manuscript are not publicly available because, per the NIH-approved ECHO Data Sharing Policy, ECHO-wide data have not yet been made available to the public for review/analysis. Requests to access the datasets should be directed to the ECHO Data Analysis Center, ECHO-DAC@rti.org.

Declarations

Ethics approval and consent to participate

The ECHO-wide protocol is under a single IRB—which is of Western Institutional Review Board (WIRB) Copernicus Group IRB. WCG IRB is registered with the Office for Human Research Protections (OHRP and FDA) as IRB00000533. Properly constituted Institutional Review Boards – either the ECHO single IRB or the ECHO cohort's local IRB – are accountable for compliance with regulatory requirements for the ECHO-wide Cohort Data Collection Protocol at participating cohort sites. Governing IRBs review ECHO protocols and all informed consent/assent forms, HIPAA authorization forms, recruitment materials, and other relevant information prior to the initiation of any ECHO-wide Cohort Data Collection Protocol-related procedures or activities. The work of the ECHO Data Analysis Center is approved through the Johns Hopkins Bloomberg School of Public Health Institutional Review Board. ECHO Cohort Investigators (or their designated study personnel) obtained written informed consent from all participants in the current study for ECHO-wide Cohort Data Collection Protocol participation and for participation in their specific cohorts.

Consent to publication

Not applicable.

Competing interests

The authors have no conflicts to declare.

Author details

¹Department of Psychiatry, Division of Developmental Neuroscience, Columbia University Irving Medical Center, NYSPI, Pardes Rm 4932, 1051 Riverside Drive, New York, NY 10032, USA. ²Department of Psychology, University of Southern California, Los Angeles, CA, USA. ³Avera Research Institute, Sioux Falls, SD, USA. ⁴Rutgers School of Public Health, Environmental and Occupational Health Sciences Institute, Piscataway, NJ, USA. ⁵Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁶Prevention Science Institute, University of Oregon, Eugene, OR, USA. ⁷Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ⁸Warren Alpert Medical School at Brown University, Providence, RI, USA. ⁹Department of Gynecology & Obstetrics, Emory University School of Medicine, Atlanta, GA, USA. ¹⁰Kaiser Permanente Northern California, Oakland, CA, USA. ¹¹Department of Pediatrics, Division of Environmental Pediatrics, New York University School of Medicine, New York, NY, USA. ¹²Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA. ¹³Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, USA. ¹⁴Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, USA. ¹⁵Harvard Medical School, Boston, MA, USA. ¹⁶Department of Psychiatry, Psychology, Neuroscience, and Obstetrics and Gynecology, University of Rochester, Rochester, NY, USA. ¹⁷Department of Pediatrics, New York University Grossman School of Medicine, New York, NY, USA. ¹⁸Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ¹⁹Kaiser Permanente Division of Research, Oakland, CA, USA. ²⁰Johns Hopkins University, Baltimore, MD, USA. ²¹Mailman School of Public Health, Columbia University, New York, NY, USA. ²²Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, NY, New York, USA. ²³Department of Psychiatry, Division of Behavioral Medicine, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.

Received: 27 May 2022 Accepted: 14 September 2022
Published online: 08 October 2022

References

- American DA. Standards of Medical Care in Diabetes-2021 Abridged for Primary Care Providers. *Clin Diabetes*. 2021;39(1):14–43.
- Zhou T, Du S, Sun D, Li X, Heianza Y, Hu G, et al. Prevalence and Trends in Gestational Diabetes Mellitus Among Women in the United States, 2006–2017: A Population-Based Study. *Front Endocrinol (Lausanne)*. 2022;13:868094.
- Wang H, Li N, Chiveste T, Werfalli M, Sun H, Yuen L, et al. IDF Diabetes Atlas: Estimation of Global and Regional Gestational Diabetes Mellitus Prevalence for 2021 by International Association of Diabetes in Pregnancy Study Group's Criteria. *Diabetes Res Clin Pract*. 2022;183:109050.
- Juan J, Yang H. Prevalence, Prevention, and Lifestyle Intervention of Gestational Diabetes Mellitus in China. *Int J Environ Res Public Health*. 2020;17(24):9517.
- Kim C. Maternal outcomes and follow-up after gestational diabetes mellitus. *Diabet Med*. 2014;31(3):292–301.
- Pantham P, Aye IL, Powell TL. Inflammation in maternal obesity and gestational diabetes mellitus. *Placenta*. 2015;36(7):709–15.
- Edalat B, Sharifi F, Badamchizadeh Z, Hossein-Nezhad A, Larijani B, Mirarefin M, et al. Association of metabolic syndrome with inflammatory mediators in women with previous gestational diabetes mellitus. *J Diabetes Metab Disord*. 2013;12(1):8.
- Richardson AC, Carpenter MW. Inflammatory mediators in gestational diabetes mellitus. *Obstet Gynecol Clin North Am*. 2007;34(2):213–24, viii.
- Vrachnis N, Belitsos P, Sifakis S, Dafopoulos K, Siristatidis C, Pappa KI, et al. Role of adipokines and other inflammatory mediators in gestational diabetes mellitus and previous gestational diabetes mellitus. *Int J Endocrinol*. 2012;2012:549748.
- Peracoli JC, Rudge MV, Peracoli MT. Tumor necrosis factor-alpha in gestation and puerperium of women with gestational hypertension and pre-eclampsia. *Am J Reprod Immunol*. 2007;57(3):177–85.
- Azami M, Badfar G, Soleymani A, Rahmati S. The association between gestational diabetes and postpartum depression: a systematic review and meta-analysis. *Diabetes Res Clin Pr*. 2019;149:147–55.
- Beka Q, Bowker S, Savu A, Kingston D, Johnson JA, Kaul P. Development of Perinatal Mental Illness in Women With Gestational Diabetes Mellitus: A Population-Based Cohort Study. *Can J Diabetes*. 2018;42(4):350.
- Bowers K, Laughon SK, Kim S, Mumford SL, Brite J, Kiely M, et al. The Association between a Medical History of Depression and Gestational Diabetes in a Large Multi-ethnic Cohort in the United States. *Paediatr Perinat Ep*. 2013;27(4):323–8.
- Clark CE, Rasgon NL, Reed DE 2nd, Robakis TK. Depression precedes, but does not follow, gestational diabetes. *Acta Psychiatr Scand*. 2019;139(4):311–21.
- Hinkle SN, Louis GMB, Rawal S, Zhu YY, Albert PS, Zhang CL. A longitudinal study of depression and gestational diabetes in pregnancy and the postpartum period. *Diabetologia*. 2016;59(12):2594–602.
- Kozhimannil KB, Pereira MA, Harlow BL. Association Between Diabetes and Perinatal Depression Among Low-Income Mothers. *Jama-J Am Med Assoc*. 2009;301(8):842–7.
- Morrison C, McCook JG, Bailey BA. First trimester depression scores predict development of gestational diabetes mellitus in pregnant rural Appalachian women. *J Psychosom Obstet Gynaecol*. 2016;37(1):21–5.
- Varela P, Spyropoulou AC, Kalogerakis Z, Voursoura E, Moraitou M, Zervas IM. Association between gestational diabetes and perinatal depressive symptoms: evidence from a Greek cohort study. *Prim Health Care Res*. 2017;18(5):441–7.
- Slomian J, Honvo G, Emons P, Reginster JY, Bruyere O. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. *Womens Health (Lond)*. 2019;15:1745506519844044.
- Wang Z, Liu J, Shuai H, Cai Z, Fu X, Liu Y, et al. Mapping global prevalence of depression among postpartum women. *Transl Psychiatry*. 2021;11(1):543.
- Wilson CA, Newham J, Rankin J, Ismail K, Simonoff E, Reynolds RM, et al. Is there an increased risk of perinatal mental disorder in women with gestational diabetes? A systematic review and meta-analysis. *Diabet Med*. 2020;37(4):602–22.
- Delanerolle G, Phiri P, Zeng Y, Marston K, Tempest N, Busuulwa P, et al. A systematic review and meta-analysis of gestational diabetes mellitus and mental health among BAME populations. *EclinicalMedicine*. 2021;38:101016.
- DeSisto CL, Kim SY, Sharma AJ. Prevalence estimates of gestational diabetes mellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007–2010. *Prev Chronic Dis*. 2014;11:E104.
- Bauman BL, Ko JY, Cox S, D'Angelo Mph DV, Warner L, Folger S, et al. Vital Signs: Postpartum Depressive Symptoms and Provider Discussions About Perinatal Depression - United States, 2018. *MMWR Morb Mortal Wkly Rep*. 2020;69(19):575–81.
- Dickens LT, Thomas CC. Updates in Gestational Diabetes Prevalence, Treatment, and Health Policy. *Curr Diabetes Rep*. 2019;19(6):33.
- Ruiz RJ, Avant KC. Effects of maternal prenatal stress on infant outcomes - A synthesis of the literature. *Adv Nurs Sci*. 2005;28(4):345–55.
- Bacon KL, Stuver SO, Cozier YC, Palmer JR, Rosenberg L, Ruiz-Narvaez EA. Perceived racism and incident diabetes in the Black Women's Health Study. *Diabetologia*. 2017;60(11):2221–5.
- Iturralde E, Hsiao CA, Nkemere L, Kubo A, Sterling SA, Flanagan T, et al. Engagement in perinatal depression treatment: a qualitative study of barriers across and within racial/ethnic groups. *BMC Pregnancy Childbirth*. 2021;21(1):512.
- Wickham H. *ggplot2: Elegant Graphics for Data Analysis* New York: Springer-Verlag; 2016 Available from: <https://ggplot2.tidyverse.org>.
- Becker RA, Wilks AR. *Maps: Draw Geographical Maps*. Available from: <https://cran.r-project.org/web/packages/maps/index.html>.
- Mclroy D. *Mapproj: Map Projections*. Available from: <https://cran.r-project.org/web/packages/mapproj/index.html>.
- Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. *J Clin Epidemiol*. 2010;63(11):1179–94.
- Choi SW, Schalet B, Cook KF, Cella D. Establishing a common metric for depressive symptoms: linking the BDI-II, CES-D, and PHQ-9 to PROMIS depression. *Psychol Assess*. 2014;26(2):513–27.
- Kaat AJ, Newcomb ME, Ryan DT, Mustanski B. Expanding a common metric for depression reporting: linking two scales to PROMIS(R) depression. *Qual Life Res*. 2017;26(5):1119–28.
- Blackwell CK, Tang X, Elliott AJ, Thomes T, Louwagie H, Gershon R, et al. Developing a common metric for depression across adulthood: Linking PROMIS depression with the Edinburgh Postnatal Depression Scale. *Psychol Assess*. 2021;33(7):610–8.
- Burlina S, Dalfrà MG, Lapolla A. Short- and long-term consequences for offspring exposed to maternal diabetes: a review. *J Matern Fetal Neonatal Med*. 2019;32(4):687–94.
- Fraser A, Lawlor DA. Long-term health outcomes in offspring born to women with diabetes in pregnancy. *Curr Diab Rep*. 2014;14(5):489.
- Walmer R, Huynh J, Wenger J, Ankers E, Mantha AB, Ecker J, et al. Mental Health Disorders Subsequent to Gestational Diabetes Mellitus Differ by Race/Ethnicity. *Depress Anxiety*. 2015;32(10):774–82.
- Beka Q, Bowker S, Savu A, Kingston D, Johnson JA, Kaul P. Development of perinatal mental illness in women with gestational diabetes mellitus: a population-based cohort study. *Can J Diabetes*. 2018;42(4):350–5 e1.
- Hamilton N, Stevens N, Lillis T, Adams N. The fourth trimester: toward improved postpartum health and healthcare of mothers and their families in the United States. *J Behav Med*. 2018;41(5):571–6.
- Gueuvoghlian-Silva BY, Torloni MR, Mattar R, de Oliveira LS, Scomparini FB, Nakamura MU, et al. Profile of inflammatory mediators in gestational diabetes mellitus: phenotype and genotype. *Am J Reprod Immunol*. 2012;67(3):241–50.
- Schiessl B. Inflammatory response in preeclampsia. *Mol Aspects Med*. 2007;28(2):210–9.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.